These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 11695565)

  • 1. CB6F1-rasH2 mouse: overview of available data.
    Usui T; Mutai M; Hisada S; Takoaka M; Soper KA; McCullough B; Alden C
    Toxicol Pathol; 2001; 29 Suppl():90-108. PubMed ID: 11695565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P53+/- hemizygous knockout mouse: overview of available data.
    Storer RD; French JE; Haseman J; Hajian G; LeGrand EK; Long GG; Mixson LA; Ochoa R; Sagartz JE; Soper KA
    Toxicol Pathol; 2001; 29 Suppl():30-50. PubMed ID: 11695560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interlaboratory comparison of short-term carcinogenicity studies using CB6F1-rasH2 transgenic mice.
    Takaoka M; Sehata S; Maejima T; Imai T; Torii M; Satoh H; Toyosawa K; Tanakamaru ZY; Adachi T; Hisada S; Ueda M; Ogasawara H; Matsumoto M; Kobayashi K; Mutai M; Usui T
    Toxicol Pathol; 2003; 31(2):191-9. PubMed ID: 12696579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neonatal mouse model: review of methods and results.
    McClain RM; Keller D; Casciano D; Fu P; MacDonald J; Popp J; Sagartz J
    Toxicol Pathol; 2001; 29 Suppl():128-37. PubMed ID: 11695548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid induction of more malignant tumors by various genotoxic carcinogens in transgenic mice harboring a human prototype c-Ha-ras gene than in control non-transgenic mice.
    Yamamoto S; Mitsumori K; Kodama Y; Matsunuma N; Manabe S; Okamiya H; Suzuki H; Fukuda T; Sakamaki Y; Sunaga M; Nomura G; Hioki K; Wakana S; Nomura T; Hayashi Y
    Carcinogenesis; 1996 Nov; 17(11):2455-61. PubMed ID: 8968063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Xpa and Xpa/p53+/- knockout mice: overview of available data.
    van Kreijl CF; McAnulty PA; Beems RB; Vynckier A; van Steeg H; Fransson-Steen R; Alden CL; Forster R; van der Laan JW; Vandenberghe J
    Toxicol Pathol; 2001; 29 Suppl():117-27. PubMed ID: 11695547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Tg rasH2 mouse in cancer hazard identification.
    Morton D; Alden CL; Roth AJ; Usui T
    Toxicol Pathol; 2002; 30(1):139-46. PubMed ID: 11890467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A perspective on current and future uses of alternative models for carcinogenicity testing.
    Goodman JI
    Toxicol Pathol; 2001; 29 Suppl():173-6. PubMed ID: 11695554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The syrian hamster embryo (SHE) cell transformation assay: review of the methods and results.
    Mauthe RJ; Gibson DP; Bunch RT; Custer L
    Toxicol Pathol; 2001; 29 Suppl():138-46. PubMed ID: 11695550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tg.AC genetically altered mouse: assay working group overview of available data.
    Eastin WC; Mennear JH; Tennant RW; Stoll RE; Branstetter DG; Bucher JR; McCullough B; Binder RL; Spalding JW; Mahler JF
    Toxicol Pathol; 2001; 29 Suppl():60-80. PubMed ID: 11695563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twenty-six-Week carcinogenicity study of chloroform in CB6F1 rasH2-transgenic mice.
    Sehata S; Maejima T; Watanabe M; Ogata S; Makino T; Tanaka K; Manabe S; Takaoka M
    Toxicol Pathol; 2002; 30(3):328-38. PubMed ID: 12051550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 26-Week carcinogenicity study of di-isodecyl phthalate by dietary administration to CB6F1-rasH2 transgenic mice.
    Cho WS; Jeong J; Choi M; Park SN; Han BS; Son WC
    Arch Toxicol; 2011 Jan; 85(1):59-66. PubMed ID: 20358181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative models for carcinogenicity testing: weight of evidence evaluations across models.
    Cohen SM
    Toxicol Pathol; 2001; 29 Suppl():183-90. PubMed ID: 11695556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Twenty-six week carcinogenicity study of ampicillin in CB6F1-TgrasH2 mice.
    Adachi T; Kuwamura Y; Fujiwara T; Tanimoto N; Nishimura T; Koguchi A; Kobayashi K; Sasaki Y; Yamaguchi C; Honda T; Kawashima K; Yuasa H; Yamamura T; Inui T
    J Toxicol Sci; 2002 Aug; 27(3):147-63. PubMed ID: 12238139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Examination of percutaneous application in a 26-week carcinogenicity test in CB6F1-TG rasH2 mice.
    Urano K; Suzuki S; Machida K; Eguchi N; Sawa N; Kikuchi K; Hattori Y; Usui T
    J Toxicol Sci; 2007 Oct; 32(4):367-75. PubMed ID: 17965551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The rasH2 transgenic mouse: nature of the model and mechanistic studies on tumorigenesis.
    Tamaoki N
    Toxicol Pathol; 2001; 29 Suppl():81-9. PubMed ID: 11695564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of IC tags in short-term carcinogenicity study on CB6F1 TGrasH2 mice.
    Urano K; Suzuki S; Machida K; Sawa N; Eguchi N; Kikuchi K; Fukasawa K; Taguchi F; Usui T
    J Toxicol Sci; 2006 Dec; 31(5):407-18. PubMed ID: 17202757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Panel discussion on the application of alternative models to cancer risk assessment.
    Pettit SD
    Toxicol Pathol; 2001; 29 Suppl():191-5. PubMed ID: 11695557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the carcinogenic potential of clofibrate in the rasH2 mouse.
    Nesfield SR; Clarke CJ; Hoivik DJ; Miller RT; Allen JS; Selinger K; Santostefano MJ
    Int J Toxicol; 2005; 24(5):301-11. PubMed ID: 16257850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Background and framework for ILSI's collaborative evaluation program on alternative models for carcinogenicity assessment. International Life Sciences Institute.
    Robinson DE; MacDonald JS
    Toxicol Pathol; 2001; 29 Suppl():13-9. PubMed ID: 11695549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.